HPN were grouped according to whether they received parenteral lipid. The control subjects were healthy volunteers. Most of the patients in the non-HPN groups (17 of 20) had Crohn disease and 11 of 20 patients in the HPN groups had Crohn disease.
We would like to draw attention to the significant differences, not discussed in the text, in percentage plasma phospholipid arachidonic acid (AA; 20:4nϪ6) among the groups. AA, along with eicosopentaenoic acid (20:5nϪ3), serves as an eicosanoid precursor; its deficiency is responsible for many of the clinical consequences of essential fatty acid deficiency. Non-HPN patients without major fat malabsorption and HPN patients receiving lipid had strikingly higher AA concentrations than did control subjects (7.8%, 10.4%, and 11.7%, respectively; both P < 0.05). Patients with short-gut syndrome and severe malabsorption and HPN patients not receiving lipid had values similar to those of control subjects (8.1% and 8.3%, respectively), presumably reflecting relative dietary deficiency of the essential fatty acid precursor, linoleic acid. Generally, AA concentrations are tightly controlled and stable across a wide range of linoleic acid intakes above a maintenance intake. AA concentrations are reduced only in a limited number of conditions, including classic essential fatty acid deficiency, prematurity or end-stage liver disease (in which hepatic enzyme immaturity or pathologic damage, respectively, prevents elongation and desaturation to AA), and increased dietary intake of eicosopentaenoic acid, which inhibits formation of AA from precursors and competes with AA for tissue incorporation (2) . Elevated AA relative to linoleic acid is rarely found to be related to diet because AA, which can enter phospholipids directly (3), is usually such a small dietary component.
We wonder whether this elevation in AA might represent a proinflammatory state and question whether provision of lipid to HPN patients as a means of normalizing linoleic acid concentrations might exacerbate the inflammation underlying Crohn disease. It would be interesting to consider patients with Crohn disease stratified for extent of malabsorption separately from other patients with fat malabsorption; such stratification has never been performed stringently. The presence of a relative increase in the ratio of AA to linoleic acid in the intestinal mucosa of patients with Crohn disease has been documented and the etio-logic importance of this finding in the development of local inflammation considered (4). Thus, this parallel finding of Jeppesen et al is a potentially important observation. If it can be confirmed that patients with Crohn disease who are not deficient in essential fatty acids (either because of only mild-to-moderate malabsorption or because of parenteral fat therapy) have an overabundance of plasma phospholipid AA, we must consider the possibility that abnormal fatty acid regulation might play an important role in the pathology of Crohn disease. This hypothesis is strengthened by the finding that fish oil, possibly by inhibiting AA formation and altering eicosanoid production, can maintain clinical remission in patients with Crohn disease (5) .
Karen C McCowen Pei Ra Ling Bruce R Bistrian
Beth Israel Deaconess Medical Center Boston, MA 02215 E-mail: bbistria@caregroup.harvard.edu
Reply to KC McCowen, PR Ling, and BR Bistrian
Dear Sir:
We wish to thank McCowen et al for their interest in our article and for addressing an intriguing hypothesis. We agree that it would be interesting to attempt to consider patients with Crohn disease, stratified for extent of malabsorption, separately from other patients with fat malabsorption in terms of the concentra-tion of the eicosanoid precursors arachidonic and eicosapentaenoic acids. However, the small number of patients investigated in this study would not allow such a stratification.
Palle Bekker Jeppesen Carl-Erik Høy Per Brøbech Mortensen
Medical Department of Gastroenterology Rigshospitalet, University of Copenhagen Blegdamsvej 9 DK-2100 Copenhagen Denmark E-mail: bekker@dadlnet.dk
Whole grains and coronary heart disease
The report in the September issue by Liu et al (1) concerning the Nurses' Health Study concluded that the strong inverse association between whole-grain intake and coronary heart disease was to a large degree not explained by the constituents of whole grains thought to be protective. The accompanying editorial (2) essentially concluded the same.
One constituent and confounder not considered in this study, nor in most studies regarding coronary heart disease and homocysteine's potentially detrimental role therein, is betaine (trimethylglycine). Betaine, although once considered a vitaminlike component (3) , is also endogenously synthesized from choline. It is found in whole grains and represents Ϸ0.5% of wheat bran and wheat germ but only 0.06% (and often < 0.02%) of white wheat flour. Choline, the endogenous betaine precursor, represents Ϸ0.2%, 0.3%, and 0.08% of wheat bran, wheat germ, and white flour, respectively (3) .
Betaine is the only non-vitamin-dependent homocysteine-lowering agent that methylates homocysteine to form methionine through a pathway that appears to be unhindered by any known genetic enzyme dysfunctions. Betaine is also considered a lipotrope, being related to lecithin and choline, and was used as such-in combination with B vitamins and liver extract-in promising clinical coronary heart disease research done by Lester M Morrison in the 1950s (4, 5) .
The almost general omission in research of betaine as a cardioprotective variable or as a confounder during the past 40 y or so is largely due to the absence of food tables that include betaine. In addition to whole grains, betaine is found in liver, eggs, and seafood. It is also found in plants such as beets and spinach, in which its role appears to be to increase resistance to drought and saline growing conditions.
The development of food tables that include betaine and its endogenous precursor choline is urgently needed to enable these confounders to be included in cardiovascular research and to close the gap of unrecognized confounders (1) . Nucleotide sequence AAC AAC GTC GTG GGC ACC Amino acid Asn Gly 1 Shown is the T-to-A substitution at nucleotide 1282 in exon 3 for the siblings and the mother and the G-to-A substitution at nucleotide 1549 in exon 4 for the siblings only. The nucleotide numbering is according to reference 3.
Eddie Vos
2 Amino acid position 41. 3 Amino acid position 75.
